Needham Downgrades Apellis Pharmaceuticals to Hold

Benzinga Newsdesk www.benzinga.com Negative 83.5%

Neg 83.5% Neu 0% Pos 0%

Needham analyst Joseph Stringer downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Buy to Hold.

Comments

No comments yet. Be the first!